Oncology Business Management | Specialty

Z-Code Identifiers Give Providers Objective Information About Molecular Tests

October 23rd 2014

Virtually everyone in the clinical laboratory business is now acquainted with Z-code identifiers. Each unique laboratory test should have a unique tracking code, even if more than one Z-code identifier is reported with a corresponding American Medical Association's Current Procedural Terminology (CPT) billing code.

How Test Reimbursement Decisions Are Made: A Leader of Medicare's MolDX Program Discusses Evaluation Process

October 21st 2014

Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.

The Promise of Big Data Gets Closer to Fulfillment

October 21st 2014

It seems like big data is everywhere these days. It's being touted as a solution for physicians and practices who would like to participate in Accountable Care Organizations (ACOs) and accountable care-like contracts with payers.

City of Hope Joins OncLive's Strategic Alliance Partnership Program

October 17th 2014

City of Hope teams with OncLive to further promote its distinctions and innovations in cancer care. As a member of OncLive's Strategic Partnership program, City of Hope will have the opportunity to promote its state-of-the-art comprehensive cancer center and the center's latest scientific discoveries, treatment and prevention strategies.

Americans Enrolled in High-Deductible Health Plans Concerned About Medical Expenses

October 15th 2014

Most privately insured Americans between the ages of 18 and 64 are satisfied with their health care plans, but for those enrolled in high-deductible health plans (HDHPs), a different story emerges.

FDA Grants Priority Review to Blinatumomab in Adult ALL

October 9th 2014

The FDA has assigned a priority review designation to blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

FDA Schedules ODAC Hearing for Panobinostat in Multiple Myeloma

October 9th 2014

The FDA has scheduled an ODAC advisory hearing to discuss the new drug application for panobinostat in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Olaparib in Ovarian Cancer

October 9th 2014

Maurie Markman on Patient-Centered Cancer Care

October 9th 2014

Herbert Irving Comprehensive Cancer Center

October 9th 2014

Latest News & Insight: October 9, 2014

October 9th 2014

2014 ESMO Congress Highlights

October 9th 2014

Revenue Cycle Management in a Post-ACA World

October 7th 2014

The Affordable Care Act (ACA) is bringing unprecedented changes to how health care is paid for in the US, and both primary care physicians and specialists need to understand how these changes will affect their revenues.

Brand-name Oral Oncologics Drive Spending Trend, Study Says

October 7th 2014

Spending on 47 currently available oral oncologic drugs has increased from $940 million in the first quarter of 2006 to $1.4 billion in the third quarter of 2011, according to results of a study by Rena M. Conti, PhD, and colleagues at the University of Chicago.

Commercial Tests Offer Guidance in Bladder, Renal, Testicular Cancers

October 7th 2014

While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.

How Oncologists Stay Current in Today's Medical Landscape

October 6th 2014

In 2014, the amount of medical and other information has only increased, and mobile devices such as smartphones and tablets make it even easier to access that data.

Is Breast Cancer Vaccination Coming?

October 1st 2014

Dr. Patrick Borgen Talks About Advances in Breast Cancer

October 1st 2014

Dr. Patrick Borgen Discusses the "Jolie Effect"

October 1st 2014

Dr. Patrick Borgen on the Future of Breast Cancer Treatment

October 1st 2014